Amyloid-Journal of Protein Folding Disorders

Papers
(The TQCC of Amyloid-Journal of Protein Folding Disorders is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Changes in the amyloid editorial board members and in editor positions303
A second case of liraglutide-type localised amyloidosis153
Impact of autonomic dysfunction in light chain amyloidosis patient with nephrotic syndrome and cardiac involvement39
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies26
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases24
Commentary to revisiting the genetic epidemiology of ATTRv in Spain: the Balearic Islands as a high-prevalence founder focus24
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis23
Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis − correlation between neurofilament light chain and nerve conduction study20
A novel transthyretin variant p.Val114Glu (Val94Glu) in an Italian patient with mixed phenotype hereditary transthyretin amyloidosis20
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey20
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange20
Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy19
Efficacy of diflunisal for hereditary transthyretin amyloidosis: the Swedish real-world experience19
Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging19
Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains17
A clinical and ECG based score to predict incident atrial fibrillation in cardiac amyloidosis: the Amy-Lyon AF score16
Evaluation of the yield index of genetic counselling for first-degree relatives of patients with hereditary transthyretin cardiac amyloidosis15
Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy15
Exploring light chain cardiotoxicity in AL amyloidosis: impact on hiPSC-derived cardiomyocyte activity14
Revisiting the genetic epidemiology of ATTRv in Spain: the Balearic Islands as a high-prevalence founder focus14
Clinical profile and outcome of AA amyloidosis associated kidney disease in India14
Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition14
Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis14
Genetic landscape of hereditary transthyretin amyloidosis in Spain: a multicentric retrospective study14
Identification of epidermal growth factor-containing fibulin-like extracellular matrix protein 1-derived amyloid deposition in a rhesus macaque13
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay13
Selective recognition of human small transthyretin aggregates by a novel monoclonal antibody13
Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survival13
Frontline Dara-CyBorD for AL amyloidosis: high response rates and cytogenetic insights from a real-world cohort12
Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice12
Left atrioventricular coupling index assessed with three-dimensional echocardiography: a prognostic marker of short-term outcomes in light-chain cardiac amyloidosis12
Electric field-induced destabilization and surface modulation of Aβ42 fibrils in molecular simulations: theoretical implications for direct current stimulation in Alzheimer’s disease12
Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures12
Clarifying the immunoglobulin light chain variable gene usage in Chinese patients with renal AL amyloidosis12
Guidelines for the management of hereditary ATTR amyloidosis 202612
Refining prognostication in systemic AL amyloidosis: limited value of dFLC11
ALyzer3D.AI: a more generalizable deep learning predictor of light chain amyloidogenicity powered by structural and evolutionary Artificial Intelligence10
Clinical and molecular insights into A97S variants in hereditary transthyretin amyloid polyneuropathy in South China10
Brain MRI in patients with V30M hereditary transthyretin amyloidosis10
Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee9
Possible transmission of leukocyte chemotactic factor 2 amyloidosis after interpopulational liver transplantation9
Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage9
Accelerated apolipoprotein A-II senile amyloidosis in a plasminogen activator inhibitor-1 knock-out model8
Change of guard at Amyloid – a tribute to outgoing Editor in Chief, Professor Per Westermark8
Involvement of bile acid in diarrhoea and therapeutic effect of colestimide in hereditary ATTR amyloidosis7
RNA-based full length immunoglobulin light chain sequencing reveals lambda constant domain mutations with potential implications for thermodynamic stability in light chain amyloidosis7
Fewer gastrointestinal events with vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy: analysis from the phase 3 HELIOS-B study7
Cold pressor test and paradoxical blood pressure reduction in light chain amyloidosis7
AA amyloidosis as an adverse event of immune checkpoint inhibitor therapy: evidence from the FDA adverse event reporting system and a systematic review7
A rare occurrence and near miss! Should a TTR gene test be routinely performed for suspected ATTR-cardiomyopathy?7
Serum peripherin as a disease biomarker in hereditary transthyretin amyloidosis: a multicenter cohort study7
Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis7
Incidence of second primary malignancies in patients with AL amyloidosis and the impact of disease stage and therapies7
Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant7
Correction7
Complete remission after patisiran treatment in a patient with nephrotic syndrome secondary to hereditary transthyretin amyloidosis (ATTR)7
Single-slide detection and typing of AL renal amyloidosis: combining mass spectrometry imaging and digital pathology6
Subtyping of cardiac amyloidosis by mass spectrometry-based proteomics of endomyocardial biopsies6
Prognostic impact of cardiac resynchronization therapy in wild-type transthyretin amyloid cardiomyopathy6
Altered connectivity of central autonomic network: effects of dysautonomia in hereditary transthyretin amyloidosis with polyneuropathy6
Enhanced analytic methodology enables postmortem diagnosis of hereditary AApoAI amyloidosis6
Proteostasis is disrupted in human endothelial cells by serum from ATTR patients and is rescued by tafamidis treatment6
Right ventricular coupling predicts cardiopulmonary fitness in cardiac transthyretin amyloidosis6
Neuropathy progression in hereditary transthyretin amyloidosis (ATTRv) patients after liver transplantation6
Incidence and predictors of sudden death in patients with cardiac amyloidosis6
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study6
0.65758204460144